Abstract 219P
Background
Tyrosine kinase inhibitor (TKI) combined with immune checkpoint inhibitor(ICI)had demonstrated efficacy as first-line therapy for mRCC patients(pts)in clinical trials. However, data on real-world outcomes were limited. Our study aimed to evaluate the effectiveness of tislelizumab plus TKI in pts with mRCC.
Methods
Demographic and clinicopathological data of pts with mRCC between July 2019 and November 2022 were retrospectively collected from Sun Yat-sen University Cancer Center. All pts received first-line treatment with TKI monotherapy (TKI group, mainly sunitinib) or tislelizumab plus TKI therapy (combination group,mainly plus axitinib). TKI group who failed first-line therapy received tislelizumab plus TKI as second-line regimen. Combination group who failed first-line therapy received TKI or ICI plus TKI as second-line regimen. Outcomes including the objective response rate (ORR), progression-free survival (PFS), PFS2 (defined as time from initial treatment to progression after first subsequent therapy or any-cause death.) and overall survival (OS) were calculated.
Results
Totally 136 pts were analyzed, with a median age of 57 (17-81) years. 72.1% were male, 71.3% had clear cell RCC, 78.8% had an IMDC intermediate/poor-risk disease, 62.5% had metastatic number≥2, metastatic organs included lung (47.1%), bone (27.9%), liver (13.2%) and brain (5.1%). The median follow-up was 26.4 (23.1-29.6) months. The combination group (n=61) had a significantly longer PFS compared with the TKI group (n=75) (median PFS (95% CI): 17.4 (13.9-20.9) vs 6.2 (5.5-6.9) months, P<0.001). Similarly, the PFS2 was longer in the combination group (median PFS2 (95% CI): 23.5 (7.7-39.3) vs 14.7 (11.1-18.3) months, P=0.011). Besides, ORR was remarkably improved in the combination group (44.3% vs 18.7%, P=0.001). Median OS was not reached for combination group and 42.9 months for TKI group (p = 0.081).
Conclusions
Our data demonstrated effectiveness of tislelizumab plus TKI as first-line treatment for mRCC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract